These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16003298)

  • 1. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms.
    Wang R; Chen K; Wen SY; Li J; Wang SQ
    Clin Pharmacol Ther; 2005 Jul; 78(1):90-2. PubMed ID: 16003298
    [No Abstract]   [Full Text] [Related]  

  • 2. Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics.
    Lee HW; Lim MS; Lee J; Jegal MY; Kim DW; Lee WK; Jang IJ; Shin JG; Yoon YR
    J Clin Pharm Ther; 2012 Feb; 37(1):105-11. PubMed ID: 21208246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
    Suzuki K; Yanagawa T; Shibasaki T; Kaniwa N; Hasegawa R; Tohkin M
    Diabetes Res Clin Pract; 2006 May; 72(2):148-54. PubMed ID: 16325295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
    Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.
    Chen SZ; Pan PP; Shen LB; Xu SS; Dai DP; Geng PW; Cai J; Cai JP; Hu GX
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):732-8. PubMed ID: 24986093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
    Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
    Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide.
    Chen K; Wang R; Wen SY; Li J; Wang SQ
    J Clin Pharm Ther; 2005 Jun; 30(3):241-9. PubMed ID: 15896241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
    Yin OQ; Tomlinson B; Chow MS
    Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride.
    Dai DP; Wang SH; Geng PW; Hu GX; Cai JP
    Basic Clin Pharmacol Toxicol; 2014 Apr; 114(4):305-10. PubMed ID: 24118918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects.
    Yoo HD; Kim MS; Cho HY; Lee YB
    Eur J Clin Pharmacol; 2011 Sep; 67(9):889-98. PubMed ID: 21476064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population.
    Lee SS; Kim KM; Thi-Le H; Yea SS; Cha IJ; Shin JG
    Ther Drug Monit; 2005 Apr; 27(2):208-10. PubMed ID: 15795654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
    Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K
    Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.
    Choi CI; Kim MJ; Chung EK; Lee HI; Jang CG; Bae JW; Lee SY
    Eur J Clin Pharmacol; 2012 Feb; 68(2):149-54. PubMed ID: 21842338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.
    Cheng Y; Wang G; Zhang W; Fan L; Chen Y; Zhou HH
    Eur J Clin Pharmacol; 2013 Mar; 69(3):407-13. PubMed ID: 22842957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.
    Niemi M; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2001 Nov; 70(5):439-45. PubMed ID: 11719730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
    Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
    Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C9 allelic variants: ethnic distribution and functional significance.
    Xie HG; Prasad HC; Kim RB; Stein CM
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1257-70. PubMed ID: 12406644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
    Niemi M; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.
    Ufer M; Kammerer B; Kahlich R; Kirchheiner J; Yasar U; Brockmöller J; Rane A
    Xenobiotica; 2004 Sep; 34(9):847-59. PubMed ID: 15742978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.
    Bae JW; Choi CI; Lee HI; Lee YJ; Jang CG; Lee SY
    Int J Clin Pharmacol Ther; 2012 Sep; 50(9):683-9. PubMed ID: 22735459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.